| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥10.5B | ¥12.2B | -14.0% |
| Operating Income | ¥-5.5B | ¥-4.0B | -37.7% |
| Ordinary Income | ¥-5.6B | ¥-3.9B | -43.1% |
| Net Income | ¥-6.3B | ¥-3.9B | -61.2% |
| ROE | -309.8% | -62.2% | - |
FY2025 results: Revenue ¥10.5B (YoY -14.0%), Operating Income ¥-5.5B (prior ¥-4.0B, deterioration of ¥1.5B), Ordinary Income ¥-5.6B (YoY -43.1%), Net Income ¥-6.3B (YoY -61.2%). The company recorded its second consecutive period of operating losses with deepening losses across all profit metrics. Operating margin deteriorated to -52.1% from -32.6% in the prior period, representing a 1,950bp decline. The primary drivers were revenue contraction combined with elevated SG&A expenses of ¥9.6B, resulting in negative operating leverage. Extraordinary losses included impairment charges of ¥0.7B. Despite losses, cash position strengthened to ¥9.9B through financing activities totaling ¥6.8B, including bond issuance and equity raising. The equity ratio deteriorated sharply to 14.6% as accumulated losses expanded to ¥-13.3B, indicating severe capital erosion. Management forecasts FY2025 full-year revenue of ¥16.0B (YoY +52.2%) but projects continued losses with operating income of ¥-3.8B and net income of ¥-3.9B, suggesting recovery remains distant.
Revenue declined ¥1.7B to ¥10.5B, representing a -14.0% YoY contraction. The reduction occurred despite inventory accumulation of ¥0.7B (+137.2% YoY), suggesting potential demand weakness or sales cycle delays. The company maintained gross profit margin at 39.1% (gross profit ¥4.1B), indicating core product profitability remained stable. However, SG&A expenses of ¥9.6B consumed 91.2% of revenue, creating a structural profitability gap. The SG&A burden increased both in absolute terms and as a percentage of sales compared to the prior period's configuration, demonstrating negative operating leverage as fixed costs outpaced revenue trends.
Operating loss expanded to ¥-5.5B from ¥-4.0B, a deterioration of ¥1.5B despite modest gross margin preservation. The operating margin of -52.1% reflects fundamental misalignment between revenue scale and cost structure. Non-operating items contributed minimal impact, with non-operating income of ¥0.1B and non-operating expenses of ¥0.2B, resulting in ordinary loss of ¥-5.6B. The gap between operating loss and net loss widened due to extraordinary losses of ¥0.7B, primarily impairment charges, which represented a non-recurring factor signaling asset revaluation. Tax expense was effectively nil given the loss position. The ¥0.7B impairment pushed net income to ¥-6.3B, a 61.2% deepening of losses YoY.
The earnings pattern represents revenue down/profit down, with both top-line contraction and bottom-line deterioration driven by high fixed cost structure and one-time impairment charges.
[Profitability] ROE of -309.8% reflects severe capital erosion as net losses consumed equity base. Operating margin deteriorated to -52.1% from -32.6% in the prior period, a decline of 1,950bp. Gross profit margin maintained at 39.1% demonstrates product-level pricing power, but SG&A ratio of 91.2% indicates structural cost burden. Net profit margin of -60.4% includes the impact of ¥0.7B impairment charge. [Cash Quality] Cash and equivalents reached ¥9.9B, providing coverage of 3.8x against current liabilities of ¥2.6B, indicating adequate short-term liquidity secured through financing activities. Operating cash flow of ¥-3.3B versus net income of ¥-6.3B produces an OCF-to-net-income ratio of 0.51x, suggesting weak cash conversion. [Investment Efficiency] Total asset turnover of 0.75x reflects subdued revenue generation relative to asset base. Fixed asset investment of ¥0.3B relative to depreciation of ¥0.5B produces a capex-to-depreciation ratio of 0.60x, indicating potential underinvestment in productive capacity. Inventory turnover days extended to 64 days as inventory balances grew ¥0.7B while sales declined, warranting monitoring for obsolescence risk. [Financial Health] Equity ratio contracted to 14.6% from 46.9% as equity declined to ¥2.0B from ¥6.3B, reflecting accumulated loss accumulation. Current ratio of 525.1% and quick ratio of 482.6% appear robust but mask structural leverage issues. Debt-to-equity ratio surged to 5.84x, significantly exceeding healthy leverage thresholds and indicating elevated financial risk. Long-term debt of ¥4.3B and bonds payable of ¥5.0B total ¥9.3B in non-current liabilities, while retained earnings stand at ¥-13.3B, demonstrating severe capital deficiency.
Operating cash flow of ¥-3.3B improved from ¥-4.9B in the prior period but remains deeply negative, representing 0.51x of net income and indicating earnings lack cash backing. The operating cash flow subtotal before working capital changes was ¥-3.3B, suggesting core business operations consumed cash. Working capital movements showed inventory increase of ¥0.7B absorbing cash, partially offset by receivables decrease of ¥2.1B which released ¥2.1B in cash as collections improved or sales declined. Payables increased ¥0.1B, providing minimal working capital relief. Interest and dividend receipts were negligible at ¥0.0B, and interest paid was similarly minimal, reflecting low debt service relative to the ¥9.3B debt load, possibly due to favorable terms or deferred payments. Investing cash flow of ¥-0.3B was primarily capital expenditure of ¥0.3B, indicating restrained investment activity. Free cash flow of ¥-3.5B reflects continued cash consumption from operations exceeding ¥3.5B. Financing cash flow of ¥6.8B provided critical liquidity through bond issuance of ¥5.0B and equity capital raising, enabling cash balance to increase ¥3.2B to ¥9.9B. The financing activities indicate external capital dependence to bridge operating cash shortfalls and fund working capital needs.
Ordinary income of ¥-5.6B versus operating income of ¥-5.5B shows net non-operating expense of approximately ¥0.1B, representing minimal impact from financial activities. Non-operating income of ¥0.1B and non-operating expenses of ¥0.2B contributed a net ¥0.1B drag, equivalent to 0.9% of revenue, indicating limited reliance on non-operating items. The composition included negligible interest income and financial gains, reflecting limited investment income generation. Extraordinary losses of ¥0.7B consisting primarily of impairment charges represent a non-recurring 6.7% of revenue impact, signaling one-time asset write-downs that depressed net income beyond operating performance. Excluding the ¥0.7B impairment, adjusted net loss would approximate ¥-5.6B, still deeply negative but aligned more closely with ordinary income. Operating cash flow of ¥-3.3B compared to net income of ¥-6.3B suggests operating cash outflow was less severe than accounting losses, partly due to non-cash impairment charges and working capital improvements from receivables collection. However, the operating cash flow remains negative, indicating the business has not yet achieved cash-generative operations. Earnings quality remains weak as losses are not offset by positive operational cash generation, and the company relied on ¥6.8B in financing activities to maintain liquidity.
Full-year guidance projects revenue of ¥16.0B, operating income of ¥-3.8B, ordinary income of ¥-3.8B, and net income of ¥-3.9B. Current period revenue of ¥10.5B represents 65.6% progress toward the ¥16.0B target, suggesting remaining periods require ¥5.5B in revenue, or approximately 52% of annual guidance in upcoming quarters. This implies a significant revenue acceleration is embedded in the forecast. Current period operating loss of ¥-5.5B exceeds the full-year guidance of ¥-3.8B operating loss by ¥1.7B, indicating the company anticipates substantial operating improvement in remaining periods, potentially through cost reduction or revenue recovery. The net income forecast of ¥-3.9B is more favorable than the current ¥-6.3B net loss, assuming no further extraordinary losses and operational improvement. EPS forecast of ¥-96.88 reflects continued dilution to 4,026K shares outstanding from 3,958K average shares. Dividend forecast remains ¥0.00, consistent with loss position. Management noted in forecast notes that projections are based on currently available information and reasonable assumptions, with actual results potentially differing materially. The business plan disclosure originally scheduled for February 2026 has been postponed to by end of March 2026, suggesting possible revisions to strategic outlook. Achievement of guidance requires quarterly revenue run-rate of approximately ¥2.8B and elimination of over ¥1.7B in quarterly operating losses, representing substantial operational turnaround from current trajectory.
Revenue recovery uncertainty: Full-year guidance assumes ¥5.5B in remaining revenue (52% of annual target) following ¥10.5B in current results, requiring significant demand rebound or new revenue streams. Historical revenue decline of -14.0% YoY and absence of disclosed order backlog or forward contract visibility create execution risk for forecast achievement.
Structural cost burden and negative operating leverage: SG&A expenses of ¥9.6B consumed 91.2% of revenue, creating ¥5.5B operating loss despite maintaining 39.1% gross margin. Fixed cost structure appears inflexible relative to revenue scale, requiring either substantial cost reduction initiatives or doubling of revenue scale to approach breakeven, neither of which have clear catalysts in disclosed information.
Capital structure fragility and refinancing risk: Debt-to-equity ratio of 5.84x with ¥9.3B in total debt against equity of only ¥2.0B, combined with accumulated deficit of ¥-13.3B and consecutive annual losses, creates covenant breach risk and potential difficulty in refinancing ¥5.0B bonds payable and ¥4.3B long-term loans upon maturity. Operating cash flow of ¥-3.3B provides no debt service capacity, forcing reliance on ¥9.9B cash reserves which are depleting at ¥3.5B annual free cash flow burn rate, providing roughly 2.8 years of runway at current consumption levels before liquidity crisis absent operational turnaround or additional capital raising.
[Industry Position] (Reference - Proprietary Analysis)
The company's profitability and financial health metrics indicate positioning at the lower end of industry distribution. Operating margin of -52.1% contrasts unfavorably against typical industry operating margins in positive territory, reflecting early-stage commercialization or operational restructuring phase. The equity ratio of 14.6% falls significantly below typical industry median ranges of 40-60%, indicating elevated leverage and capital structure stress. ROE of -309.8%, while distorted by negative earnings and eroded equity base, signals fundamental misalignment with industry profitability norms where positive mid-to-high single digit ROE is standard. Historical trend shows consecutive periods of negative operating income and contracting revenue, diverging from industry patterns of growth and profitability expansion. The company's reliance on external financing of ¥6.8B to maintain ¥9.9B cash position contrasts with industry peers typically generating positive operating cash flow. Gross margin of 39.1% appears competitive, suggesting product-level economics are within industry range, but SG&A burden of 91.2% of revenue is structurally misaligned with scalable business models. Without segment-level benchmarking data, overall assessment indicates the company is in turnaround or scale-up phase with financial metrics reflecting transitional challenges rather than steady-state industry positioning.
Liquidity buffer provides near-term runway but operational turnaround urgency: Cash position of ¥9.9B secured through ¥6.8B financing activities offers approximately 2.8 years of liquidity at current ¥-3.5B annual free cash flow burn rate, creating a finite window for achieving operational cash flow breakeven. The company's ability to reduce SG&A from ¥9.6B levels or scale revenue toward the ¥16.0B guidance target represents the critical path to self-sustaining operations. Progress toward quarterly breakeven and SG&A ratio reduction below 70% of revenue would signal successful turnaround execution.
Capital structure requires monitoring for recapitalization risk: Debt-to-equity ratio of 5.84x with ¥9.3B debt against ¥2.0B equity and ¥-13.3B accumulated deficit indicates balance sheet stress requiring either sustained return to profitability to rebuild equity organically, or potential future capital restructuring including additional equity raises, debt conversion, or refinancing. Bond maturity schedules and covenant compliance will be key monitoring points, as consecutive losses and negative cash flow may trigger financial covenant reviews.
Full-year guidance embeds aggressive operating inflection: Management's full-year targets require remaining quarters to generate ¥5.5B revenue (implying ¥2.8B quarterly run-rate versus ¥10.5B current result) while narrowing operating losses by ¥1.7B from current ¥-5.5B level. Achievement would demonstrate demand recovery and cost leverage, while shortfalls would necessitate guidance revision and intensify capital adequacy concerns. Quarterly revenue trajectory, SG&A trend, and inventory turnover (currently 64 days with ¥1.1B balance) serve as early indicators of forecast realization probability.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.